Biosimilar Infliximab IBD Drug Shown to Be as Effective and Safe as Original Therapy

Biosimilar Infliximab IBD Drug Shown to Be as Effective and Safe as Original Therapy
Celltrion Healthcare recently presented positive clinical results of recent studies evaluating the efficacy and safety of switching from the original infliximab therapy (RMP) to the biosimilar infliximab Remsima® treatment in patients with inflammatory bowel disease (IBD). The results were presented at the United European Gastroenterology Week (UEG Week) 2015. Biosimilar infliximab Remsima is a monoclonal antibody approved

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *